Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Zacks 12/13 21:40

Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma

Barchart12/10 20:26

Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024

Benzinga12/10 14:58

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

GlobeNewswire12/10 10:00

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

Benzinga11/12 20:00

HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

Benzinga11/12 19:45